SCHEMBL2995288

SCHEMBL2995288

CC(=O)c1cn(S(=O)(=O)c2ccccc2)c2nccc(-c3ccccc3)c12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTR6 P50406 6/20 0.41
CYP2C19 P33261 1/20 0.40
PLK1 P53350 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PKM P14618 1/20 0.39
ELAVL1 Q15717 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
BRD4 O60885 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237471 0.84 LMNA (0.51) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2999849 0.82 LMNA (0.49) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2986139 0.81 LMNA (0.47) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2993407 0.81 LMNA (0.47) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2998178 0.80 LMNA (0.46) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2995312 0.79 SMN1; SMN2 (0.46) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2994911 0.79 LMNA (0.46) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL12346964 0.78 HTR6 (0.49) LMNASMN1; SMN2HTR6PIK3CAMTOR
SCHEMBL2986196 0.76 LMNA (0.43) LMNASMN1; SMN2HTR6CYP2C19PLK1
SCHEMBL2997418 0.76 LMNA (0.42) LMNASMN1; SMN2HTR6CYP2C19PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125803-B1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NAT RECH SCIENT (FR) 2013-04-10 EP disclosed
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184790-A1 PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF BAD, PPOX, CASP3 LMNA 4217/4885SMN1; SMN2 954/4885HTR6 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.